November 08, 2005 10:00 ET

New Study Finds that Second-Hand Smoke Exposure Doubles Lung Cancer Risk; Nymox TobacAlert™ Product Detects Second-Hand Smoke Exposure

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Nov 8, 2005) -

A new study by researchers at the M. D. Anderson Cancer Center in Houston has found that second-hand smoke exposure doubles the risk of lung cancer in persons who have never smoked (Int J Cancer Oct 10 2005; advanced online publication). The researchers compared the reported second-hand smoke exposure of 280 lung cancer patients with 242 healthy matched controls in making their findings. The study is consistent with earlier epidemiological studies which have linked second-hand smoke exposure to lung cancer. Almost one fourth of lung cancer cases among never smokers have been attributed to exposure to second-hand smoke.

Nymox Pharmaceutical (NASDAQ:NYMX) makes TobacAlert™, an easy-to-use, cost-effective product that allows for on-site testing for second-hand smoke exposure. TobacAlert™ can be used at home, at school or in the workplace. No instruments are required and results are provided within minutes.

Second-hand smoke exposure is increasingly recognized as a major public health risk, particularly for children, pregnant women and people with asthma or heart disease. Second-hand smoke has been linked to increased risk of respiratory problems, lung, breast and other cancers, heart disease, and poor pregnancy outcomes and is classified as a class A carcinogen (the most serious category) by the U.S. Environmental Protection Agency. According to the California Air Resources Board, an estimated 50,000 deaths occur from second hand smoke exposure in the U.S. alone.

TobacAlert™ is available at over 5,400 CVS/pharmacy® stores across the U.S. as well as online at www.cvs.com. More information is available at www.tobacalert.com.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX